GPCM
PRTK

Granite Point Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Granite Point Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-26,400
Closed -$473K – 128
2017
Q4 		$473K Hold
26,400
– – 0.05% 81
2017
Q3 		$663K Hold
26,400
– – 0.14% 70
2017
Q2 		$636K Buy
+26,400
New +$584K 0.16% 73

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Granite Point Capital Management's PRTK Position: Q1 2018 in Review

Granite Point Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2018, closing a stake of 26,400 shares — an estimated $473K sold.

Granite Point Capital Management first reported a position in PRTK in Q2 2017 and held it in 3 quarters. The position peaked at $663K in Q3 2017. 114 funds tracked by Wall St. Rank hold PRTK as of Q1 2018.

  • Granite Point Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Granite Point Capital Management sold 26,400 Paratek Pharmaceuticals, Inc. shares in Q1 2018, an estimated $473K.
  • Granite Point Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
  • Granite Point Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $663K in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2018.

Based on Granite Point Capital Management's 13F filing for Q1 2018, filed 15 May 2018.